Summary
8 Major Markets Covered!
Argentina, Brazil, Chile, Colombia,Cuba,Mexico,Peru And Venezuela.
Highlights From The Region:
Argentina
The Pharmaceutical Market Is Valued At Us$4.7 Billion At Retail Prices In 2007. Pharmaceutical Production, Distribution And Sales Are Dominated By The Leading 20 Pharmaceutical Manufacturers. Pharmaceutical Production Is Still Very High, Accounting For 51% Of The Market. Foreign Producers Of Branded Pharmaceuticals Are Still Recovering From The Peso's Devaluation And Some Have Sold Their Manufacturing Plants. In 2005, Generic Prescribing Represented 79% Of The Total In The Federal Capital And Gran Buenos Aires, And 71% In The Rest Of The Country.
Brazil
The Pharmaceutical Market Is Rapidly Recovering, With 18% Growth In Net Dollar Values In 2006. Including Taxes, The Market Is Estimated At Us$13.6 Billion In 2007, Equivalent To Us$72 Per Capita. Generics Are Expected To Represent 20% Of The Pharmacy Sector By 2009. The Industry Believes That Price Controls Are Restricting Drug Consumption And Limiting Short-Term Investments. One Of The Challenges Of The Ministry Of Health Is To Resolve Anvisa's Bureaucracy And Open Up The Market.
Chile
The Pharmaceutical Market Is Valued At Us$1.5 Billion At Retail Prices In 2007. The Pharmacy Sector Was Estimated To Be Us$735 Million At Manufacturers' Prices By August 2005. By Value, Domestic Manufacturers Have 60% Of The Pharmacy Sector And 90% Of The Hospital Sector. Tough Competition Arises From The Three Pharmacy Chains Controlling 90% Of The Pharmacy Sector. Most Of The International Producers Are Importers In Chile. The Ministry Of Health And The Institute Of Public Health Are Performing Bioequivalence Tests In Selected Active Ingredients.
Colombia
The Pharmaceutical Market Is Estimated At Us$1.8 Billion In 2007. At Manufacturers' Prices, The Pharmacy Sector Was Valued At Us$891 Million And The Institutional Sector At Us$410 Million In 2004. The Healthcare Reform Programme Has Been Instrumental In Boosting Consumption Of Pharmaceuticals, But Growth Has Been Largely In Volume Terms. The Majority Of The Market Is Supplied By The Relatively Well-Developed Domestic Industry. If Ratified, The Free Trade Agreement (Fta) Between The Usa And Colombia Will Result In Further Intellectual Property Enforcements Which Might Affect The Indigenous Industry.
Mexico
The Pharmaceutical Market Is The Leading Latin American Market, Valued At Us$14.1 Billion At Retail Prices In 2007. In 2005, The Senate Approved The Reform Of Article 376 Of The General Health Law, Which Means That Product Registrations Are Valid For A Five-Year Period. Only A Few Products Are Registered As Interchangable Generics, But There Is A Wave Of Generic Producers Looking For Business Opportunities In Mexico. As The Market Is Becoming Less Competitive, Distributors Are Demanding Higher Wholesale Margins. The Retail Pharmacy Sector, Traditionally Highly Fragmented, Is Being Consolidated By Large Pharmacy Chains.
Peru
The Pharmaceutical Market Is Valued At Us$1.0 Billion At Retail Prices In 2007. At Manufacturers' Prices, The Pharmacy Sector Accounts For 72% Of The Market In 2007, Equal To Us$562 Million, And The Hospital Sector For 28%, Equal To Us$219 Million. Preferential Customs Duties And Product Registration Continue Towards Latin American Countries. The Market Is Still Dominated By Imports Of Original Drugs, Almost Exclusively Consumed By The Pharmacy Sector, And Locally Produced Branded Generics And Generics Under International Common Denomination (Icd), Consumed By The Pharmacy And Hospital Sectors. The Fta With The Usa Will Result In Further Intellectual Property Standards For The Pharmaceutical Industry.
Venezuela
Venezuela Is The Fourth Largest Market In The Region, Valued At Us$4.0 Billion At Retail Prices In 2007. In Spite Of Price Controls, The Pharmacy Sector Grew By 18.8% In 2005, Reaching Us$2.1 Billion At Manufacturers' Prices. Future Market Expansion Will Depend Heavily On Imports, Which Are Controlled. As A Percentage Of The Pharmacy Market, Domestic Production Has Decreased In Recent Years, From Representing 95% In 1995 To 55% In 2004. In The Hospital Sector, Domestic Production Accounts For 60% Of The Total. The Patent Office Is Ineffective For The Research-Based Industry. Gmp Standards, Under Who Technical Report Series No. 823, Were Expected To Be Enforced In February 2005, But The Domestic Industry Has Asked For A Transition Period Of Three To Five Years. Exports Are Marginal Due To A Lack Of Quality Standards.
- For Every Market
- Market Outlook
- Current Market Size
- Unique 5-Year Market Projections To 2012
- Market Outlook
- Comment & Rating, Covering 8 Key Areas Such As Use Of Generic Drugs, Intellectual Property, Pricing And The Health Systems
- Market Structure
- Statistical Data On Imports And Exports
- Market Developments, Covering Recent And Impending Developments With Respect To Key Issues Such As Regulation, Health Facilities, Funding And
- Government Policy
- Key National Data Projections
- For Every Market
- Background Data
- Population Data, Including Growth Trends And Age Structure
- Demographic Indicators Detailing Principal Causes Of Death And Morbidity
- Healthcare System
- Organisation & Administration
- Health Expenditure
- Expenditure By Source Of Funding And Type
- Hospital Services
- Hospital Data Such As Beds By Type, Region, Specialty, Patient Admissions And Surgical Procedures
- Outpatient Care
- Medical Personnel
- Data On Healthcare Professionals Covering Such Areas As Doctors By Specialty, Nursing Staff And Dentists
- Accessing The Pharma Market
- Regulatory Environment
- Distribution Guide And Trade Fair Information
- Domestic Production
- Contact Details
- For Healthcare Organisations And Trade Associations
The Pharmaceutical Markets In Latin America Are Worth Us$41 Billion - And Growing Fast!
The Eight Latin American Markets Covered By Espicom Represent A Market Of 468 Million People With A Gdp Of Us$2.7 Trillion In 2007. Fuelled By Mexico, Brazil, Argentina And Venezuela, They Are Expected To Represent A Market Value Of Us$63 Billion At Retail Prices By 2012.
The Region Aims To Increase Its Global Position, In An Effort To Counteract Other Emerging Markets, Particularly China And India. The Mercosur And Andean Groups, However, Have Proved To Be Quite Impractical To Align Its Members In A Common Front.
Bilateral Free Trade Agreements With The Usa Continue, Uruguay Being The Last Wishing To Follow Chile's Successful Move; Peru And Colombia Are On Their Way. Opportunities Remain As Argentina Is Mirroring Brazil In Order To Increase Its Industrial Capabilities Whilst Mexico Is Keeping Its Pace.Combined Domestic Production Stood At Us$17.9 Billion In 2004, Led By Mexico (Us$8.0 Billion) And Brazil (Us$5.8 Billion). Pharmaceutical Imports Increased To A Combined Us$7.8 Billion Whilst Pharmaceutical Exports Rose To Us$2.4 Billion In 2005. Brazil Had The Highest Negative Balance Of Trade, Valued At Us$2.1 Billion, Followed By Mexico (Us$1.4 Billion).These Reports Analyse The Issues
That Is Why Espicom Business Intelligence Has Published These New Management Reports The Outlook For Pharmaceuticals In Latin America To 2012. Each Report Provides An Individual And Highly-Detailed Analysis Of Each Market, Looking At The Key Regulatory, Political, Economic And Corporate Developments In The Wider Context Of Market Structure, Service And Access. The Reports Are Available Individually Or As A Discounted Collection.
|
